Releases - Aerocrine

View:
 

Found press releases

 

Aerocrine’s rights issue oversubscribed

5/16/2012 2:00 AM EST
Not for publication, release or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Japan or New Zealand.

Aerocrine’s rights issue with pre-emptive rights for the company's shareholders and the holders of the company’s convertible bonds 2010/2015 has been oversubscribed and the underwriting commitments will, accordingly, not be utilized. The...

Trend Continues as BlueCross BlueShield of Louisiana Retires Negative FeNO Medic...

5/7/2012 2:00 AM EST
SOLNA, Sweden - 7 May, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that BlueCross BlueShield of Louisiana has retired its negative coverage medical policy for FeNO testing. The policy change became effective May 3, 2012.
On May 3, 2012, BlueCross BlueShield of Louisiana retired their negative coverage policy regarding Aerocrine’s asthma device which measures Fractional exhaled Nitric Oxide (FeNO)...

Aerocrine announces supplement to prospectus

5/4/2012 10:00 AM EST
Not for publication, release or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Japan or New Zealand.

Aerocrine announces a supplement to the prospectus that was made public on 17 April 2012. The supplement has been prepared as a result of the following three events;

· Aerocrine announced on 30 April 2012, after several years of...

Aerocrine requests conversion of convertible loan

5/4/2012 2:01 AM EST
SOLNA, Sweden - May 4 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) today announces that the company requested the conversion of the outstanding convertible loan, of 112 500 000 SEK, to shares per the terms of the convertible. The effect is that an additional 12,857,143 shares will be issued at a conversion price of 8.75 SEK per share.
The effect of the conversion will be to increase the Company’s equity...

Report from the 2012 Annual General Meeting in Aerocrine

5/4/2012 2:00 AM EST
The Annual General Meeting (AGM) in Aerocrine AB (NASDAQ OMX Stockholm: AERO) was held on Thursday, May 3, 2012, in Stockholm
The parent company’s and the group’s income statements and balance sheets were adopted. It was resolved that no dividend shall be paid and that the year’s loss shall be carried forward.

The AGM resolved in accordance with the proposal by the Board to amend § 7 of the Articles of...

Interim report January – March 2012

5/3/2012 2:00 AM EST
Record sales and continued increase of covered lives in the US.
January – March 2012

· Global Net sales grew by 76% to SEK 39.0m (22.2). Adjusted for currency fluctuations, net sales rose by 72%
· The worldwide number of NIOX MINO® repeat tests sold increased by a total of 47% and for clinical use in the US by 112%
· The loss after tax amounted to SEK 39.1m (26.9), corresponding to a loss per share before...

Aerocrine, AB announces positive settlement of $1.320MM USD in Aperion bankruptc...

4/30/2012 2:00 AM EST
SOLNA, Sweden- 30 April, 2012-Aerocrine AB (NASDAQ OMX Nordic Exchange: AERO) today announced that after several years of litigation, the bankruptcy court overseeing the claims to the Aperion estate has authorized the trustee to pay Aerocrine $1.3 million dollars in a compromise against claims.
The United States Bankruptcy Court, Northern District of California, San Francisco Division, presided over by the...

Aerocrine AB announces new US leadership

4/18/2012 2:00 AM EST
SOLNA, Sweden – 18 April, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that Mr. Ken Marshall will assume responsibility for US Operations atAerocrine, Inc. effectively immediately.
Mr. Marshall has over 20 years of experience in global commercial operations spanning general and specialty businesses for both drug and device. This experience includes marketing, sales, health economic/payer strategy...

Aerocrine announces prospectus regarding rights issue

4/17/2012 2:15 PM EST
Not for publication, release or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Japan or New Zealand.
Press release, 17 April 2012

The prospectus relating to Aerocrine’s rights issue is now available at www.aerocrine.com and www.remium.com and at Aerocrine’s offices, Sundbybergsvägen 9, SE-171 73 Solna, Sweden. The prospectus can also...

New Hampshire’s Medicaid program adds Aerocrine’s FeNO test to their fee schedul...

4/12/2012 2:00 AM EST
SOLNA, Sweden- 12 April, 2012-Aerocrine AB (OMX Nordic Exchange: AERO) today announced that New Hampshire’s Medicaid program adds FeNO reimbursement coverage, bringing the total to 32 states and the District of Columbia that now cover this test which is used in the assessment and management of asthma
The State of New Hampshire has included Aerocrine’s test of fractional exhaled nitric oxide (FeNO) to the...

Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammatio...

View more


  CONTACT